Semaglutide cuts major heart events, but researchers still cannot fully explain why

Wegovy Users with Heart Disease May Get Protection Beyond Weight Loss, but Researchers Still Cannot Explain Why

A new SELECT analysis finds Wegovy's heart benefit is not fully explained by weight loss or other known risk factors. Here is what it means for patients.

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.